CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Fecal Microbiota Transplantation (FMT)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02770326
NCT02770326N/ACompleted
CompareCT.gov

Safety of Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection in Patients With Solid Tumors

Memorial Sloan Kettering Cancer Center·interventional·Posted May 12, 2016·Updated Apr 8, 2025

In Brief

A clinical study evaluating Fecal Microbiota Transplantation (FMT) for C. Difficile Infection and Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety of FMT in patients with C. difficile and cancer. In previous other studies, FMT has been shown to cure C. difficile when antibiotics have failed, but most of these studies have not included patients with cancer. The investigators want to prove that FMT is safe in this group of people so that doctors will feel more comfortable prescribing it for their patients with cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC. Difficile Infection, Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 12, 2016
Enrollment StartMay 10, 2016
Primary CompletionFeb 16, 2024
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 10.1 years ago

Interventions

Fecal Microbiota Transplantation (FMT)biological